News Releases

–New data show effectiveness of sebetralstat in reducing anxiety during attacks; supports need for oral on-demand option to treat attacks earlier and more often– –Patient perspectives spotlight the prevalence of anxiety when faced with administering injectable on-demand therapies– CAMBRIDGE, Mass.

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Oct. 2, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted six newly-hired employees inducement options to purchase an aggregate of 31,000 shares of

– Submissions support KalVista’s mission of building a global footprint for sebetralstat to address the significant unmet need for people with HAE worldwide – – If approved, sebetralstat will be the first, oral on-demand treatment for HAE – CAMBRIDGE, Mass.

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 26, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV),   today announced the acceptance of multiple abstracts at the HAEi Global Angioedema Forum (GAF) taking place in Copenhagen, Denmark   October 4-5, 2024 .

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 10, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that its management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19th, 2024 at 10:20 a.m.

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 10, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a demonstrated track record

–Patient perspectives shed additional light on the challenges of treating hereditary angioedema attacks with injectable on-demand therapies– –New analyses of sebetralstat clinical trials bolster efficacy and safety profile – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep.

–U.S. FDA accepts NDA for sebetralstat for oral on-demand treatment of HAE; Sets PDUFA goal date of June 17 , 2025– –European Medicines Agency (EMA) validated the submission of Marketing Authorization Application (MAA) for sebetralstat– CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep.

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 4, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 55,000 shares of

– If approved, sebetralstat will be the first, oral on-demand treatment for HAE – – FDA PDUFA goal date of June 17, 2025 – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), today announced that the U.S.